ARKGvsSBIOETF Comparison
VS
ARK Genomic Revolution ETF (ARKG) belongs to the BioTech & Genomics segment. ALPS Medical Breakthroughs ETF (SBIO) is part of the Tomorrow's Treatments segment. ARKG's top 1 sector exposures are Healthcare. In contrast, SBIO's top sector exposures are Healthcare and Non-Corporate. ARKG is more expensive with a Total Expense Ratio (TER) of 0.75%, versus 0.5% for SBIO. ARKG is up 55.92% year-to-date (YTD) with +$33M in YTD flows. SBIO performs worse with 23.92% YTD performance, and +$75M in YTD flows. Run a side-by-side ETF comparison of ARKG and SBIO below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
ARKG vs SBIO performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/11/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | ARKG SBIO | +2.07%-5.45% | +35.35%+21.45% | +55.92%+23.92% | +73.72%+71.89% | +44.39%+119.59% | -43.98%+42.12% |
| Flows | ARKG SBIO | +$57M+$31M | +$127M+$51M | +$33M+$75M | +$51M+$84M | -$523M+$56M | -$2.24B+$17M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | ARKG SBIO | +42.98%+31.69% | +43.87%+30.93% | +43.91%+31.09% | +46.35%+33.90% |
| Max drawdown | ARKG SBIO | -13.89%-10.36% | -27.52%-12.63% | -46.41%-42.12% | -78.04%-52.50% |
| Max drawdown duration | ARKG SBIO | 32d23d | 126d60d | 882d331d | 1818d1479d |
Trading data
ARKG | SBIO | |
Last sale 9/11/2026 at 1:30 PM | $45.56 | $63.29 |
| Previous close 09/10/2026 | $45.38 | $63.80 |
| Consolidated volume 09/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
ARKG
is actively managed and doesn’t replicate an indexARKG | SBIO | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/11/2026 at 1:30 PM
Live
Closed
ARKG | SBIO | |
|---|---|---|
| Last price | $45.56 | $63.29 |
| 1D performance | +0.40% | -0.80% |
| AuM | $1.83 B | $232.85 M |
| E/R | 0.75% | 0.5% |
Characteristics
ARKG | SBIO | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Ark Investment | ALPS |
| Benchmark | - | S-Network Medical Breakthroughs Index |
| N° of holdings | 31 | 104 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | April 2, 2019 | December 30, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
ARKG
USA
88.43%
Other
11.57%
SBIO
USA
89.23%
Other
10.77%
Sectors
ARKG
Healthcare
97.99%
Other
2.01%
SBIO
Healthcare
100.02%
Other
-0.02%
Advertisement
Diversification
ARKG
Total weight of top 15 holdings out of 15
75.55%
SBIO
Total weight of top 15 holdings out of 15
42.78%
Top 15 holdings
Data as of July 31, 2026
ARKG
10X Genomics, Inc.
9.41%
Twist Bioscience Corp.
7.74%
Tempus AI, Inc.
6.57%
CRISPR Therapeutics AG
6.30%
Personalis, Inc.
5.48%
Absci Corp.
5.15%
Guardant Health, Inc.
4.75%
Illumina, Inc.
4.75%
Eli Lilly & Co.
4.69%
CareDx, Inc.
4.31%
Natera, Inc.
4.14%
Beam Therapeutics, Inc.
3.78%
Compass Pathways Plc
3.26%
Recursion Pharmaceuticals, Inc.
2.63%
Adaptive Biotechnologies Corp.
2.58%
SBIO
Crinetics Pharmaceuticals, Inc.
4.75%
Apogee Therapeutics, Inc.
4.48%
CG Oncology, Inc.
3.39%
Xenon Pharmaceuticals, Inc.
3.26%
Dianthus Therapeutics, Inc.
3.15%
Oruka Therapeutics, Inc.
3.14%
Travere Therapeutics, Inc.
2.80%
Definium Therapeutics, Inc.
2.56%
ACADIA Pharmaceuticals, Inc.
2.39%
Veradermics, Inc.
2.36%
Dyne Therapeutics, Inc.
2.25%
Edgewise Therapeutics, Inc.
2.23%
Relay Therapeutics, Inc.
2.22%
Denali Therapeutics, Inc.
1.97%
Structure Therapeutics, Inc.
1.84%
Frequently asked questions about ARKG and SBIO
How have the ARKG and SBIO ETFs performed in 2026?
As of September 11, 2026, ARKG is up 55.92% year-to-date (YTD), while SBIO has returned 23.92%. That puts ARKG better performer ahead so far this year.
Which ETF is attracting more investor money: ARKG or SBIO?
Year-to-date, the ARKG ETF saw +$33M in flows, compared to +$75M for SBIO.
Which ETF is more volatile: ARKG or SBIO?
Over the past year, ARKG had a volatility of 43.87%, while SBIO experienced 30.93%.
Which ETF is bigger: ARKG or SBIO?
As of September 11, 2026, ARKG holds $1.83 B in assets under management (AUM), while SBIO manages $232.85 M.
What sectors do the ARKG and SBIO ETFs invest in?
ARKG leans toward sectors like Healthcare. Meanwhile, SBIO focuses on Healthcare.
What are the top holdings of the ARKG ETF and SBIO ETF?
ARKG top holdings include 10X Genomics, Inc., Twist Bioscience Corp. and Tempus AI, Inc.. SBIO holds in its top three: Crinetics Pharmaceuticals, Inc., Apogee Therapeutics, Inc. and CG Oncology, Inc..
Which ETF is more diversified: ARKG or SBIO?
ARKG holds 31 securities with 75.55% of its assets in the top 15. SBIO has 104 securities and a top 15 weight of 42.78%.
Advertisement
Latest news about ARKG & SBIO
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
Biotech ETFs – Investing in Health Innovation
July 21, 2022
ARKG
Advertisement
Advertisement
